Cancer Biomarkers Market | Ongoing Trends and Recent Developments | Major Key Players like Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies

The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.

What the Market Looks Like?

Predicted to grow at a CAGR of 12.2% during the forecast period, the global Cancer Biomarkers market is estimated to reach USD 20.48 billion by 2022. North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe.

Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers). The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.

Based on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers). During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202&utm_source=openpr&utm_medium=referral&utm_campaign=paidpr

What Drives the Market?

The growth of the global market for Cancer Biomarkers is primarily influenced by the following factors:

Technological Advancements
Rising Incidence of Cancer
Increasing Use of Cancer Biomarkers in Drug Discovery and Development
Increasing Research on Cancer Biomarkers
Geographical growth scenario of Cancer Biomarkers Market

The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. While North America (comprising the U.S. and Canada) is expected to account for the largest share of the global cancer biomarker market in 2017. The Asia-Pacific cancer biomarker market, particularly in China, Japan, and India is expected to witness high growth in the forecast period. Factors such as rising incidence of cancer, increasing use of biomarker tests for diagnostic purposes, expansions of major pharmaceutical companies in emerging Asian economies, and government support to research institutes and universities are further drive the growth of this market in the APAC region.

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=202&utm_source=openpr&utm_medium=referral&utm_campaign=paidpr

Leading market players and strategies adopted

The prominent players in the Cancer Biomarkers market include Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).

Request Bundle Reports:
https://www.marketsandmarkets.com/RequestBundleReport.asp?id=202&utm_source=openpr&utm_medium=referral&utm_campaign=paidpr

Contact:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email:sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.